SEARCH

SEARCH BY CITATION

References

  • 1
    Angulo P, Lindor K. Primary sclerosing cholangitis. HEPATOLOGY 1999; 30: 325332.
  • 2
    Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995; 332: 924933.
  • 3
    Vierling JM. Hepatobiliary complications of ulcerative colitis and Crohn's disease. In: ZakimD, BoyerTD, eds. Hepatology. A Textbook of Liver Disease. Volume 2. 4th ed. Philadelphia, PA: Saunders, 2003; 12211272.
  • 4
    Spurkland A, Saarinen S, Boberg KM, Mitchell S, Broome U, Caballeria L, et al. HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens 1999; 53: 459469.
  • 5
    Donaldson PT, Albertini RJ, Krawitt EL. Immunogenetic studies in autoimmune hepatitis and primary sclerosing cholangitis. In: KrawittEL, WiesnerRH, Nishioka, eds. Autoimmune Liver Diseases. 2nd ed. Amsterdam, the Netherlands: Elsevier Science; 1998: 141165.
  • 6
    Sasatomi K, Noguchi K, Sakisaka S, Sata M, Tanikawa K. Abnormal accumulation of endotoxin in biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 1998; 29: 409416.
  • 7
    Lichtman SN, Keku J, Clark RL, Schwab JH, Sartor RB. Biliary tract disease in rats with experimental small bowel bacterial overgrowth. HEPATOLOGY 1991; 13: 766772.
  • 8
    Lichtman SN, Okoruwa EE, Keku J, Schwab JH, Sartor RB. Degradation of endogenous bacterial cell wall polymers by muralytic enzyme mutanolysin prevents hepatobiliary injury in genetically susceptible rats with experimental intestinal bacterial overgrowth. J Clin Invest 1992; 90: 13131322.
  • 9
    Lichtman SN, Keku J, Schwab JH, Sartor RB. Hepatic injury associated with small bowel bacterial overgrowth in rats is prevented by metronidazole and tetracycline. Gastroenterology 1991; 100: 513519.
  • 10
    Krehmeier U, Bardenheuer M, Voggenreiter G, Obertacke U, Schade FU, Majetschak M. Effects of antimicrobial agents on spontaneous and endotoxin-induced cytokine release of human peripheral blood mononuclear cells. J Infect Chemother 2002; 8: 194197.
  • 11
    Leite AZ, Sipah AM, Damiao AO, Coelho AM, Garcez AT, Machado MV, et al. Protective effect of metronidazole on uncoupling mitochondrial oxidative phosphorylation induced by NSAID: a new mechanism. Gut 2001; 48: 163167.
  • 12
    Mahadevan U, Bass NM. Sclerosing cholangitis and recurrent pyogenic cholangitis. In: FeldmanM, FriedmanLS, SleisengerMH, eds. Sleisenger & Fordtran's Gastrointestinal and Liver Disease. Volume 1. 7th ed. Philadelphia, PA: Saunders, 2002: 11311152.
  • 13
    Lindor KD. Ursodiol for primary sclerosing cholangitis. N Eng J Med 1997; 336: 691695.
  • 14
    Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001; 121: 900907.
  • 15
    Mistilis SP, Skyring AP, Goulston SJM. Effect of long term tetracycline therapy, steroid therapy and colectomy in pericholangitis associated with ulcerative colitis. Australas Ann Med 1965; 14: 286294.
  • 16
    Grundy SM, Ahrens EH Jr, Miettinen TA. Quantitative isolation and gas-liquid chromatographic analysis of fecal bile acids. J Lipid Res 1965; 6: 397410.
  • 17
    Ludwig J, LaRusso NF, Wiesner RH. Primary sclerosing cholangitis. In: PetersR, CraigJR, eds. Liver Pathology. Contemporary Issues in Surgical Pathology. New York, NY: Churchill Livingstone, 1986: 193213.
  • 18
    Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer P. Classification of chronic hepatitis: diagnosis, grading, and staging. HEPATOLOGY 1994; 6: 15131520.
  • 19
    Craig DA, MacCarty RL, Wiesner RH, Grambsch PM, LaRusso NF. Primary sclerosing cholangitis: value of cholangiography in determining the prognosis. AJR Am J Roentgenol 1991; 157: 959964.
  • 20
    Kim WR, Poterucha JJ, Wiesner RH, LaRusso NF, Lindor KD, Petz J, et al. The relative role of Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. HEPATOLOGY 1999; 29: 16431648.
  • 21
    Lindor KD, Wiesner RH, Colwell LJ, Steiner B, Beaver S, LaRusso NF. The combination of prednisone and colcicine in patients with primary sclerosing cholangitis. Am J Gastroenterol 1991; 86: 5761.
  • 22
    Allison MC, Burroughs AK, Noone P, Summerfield JA. Biliary lavage with corticosteroids in primary sclerosing cholangitis: A clinical, cholangiographic and bacteriological study. HEPATOLOGY 1986; 3: 118122.
  • 23
    van Hoogstraaten HJF, Vleggaar FP, Boland GJ, van Steenbergen, Griffioen P, Hop WCJ, et al. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Am J Gastroenterol 2000; 95: 20152022.
  • 24
    Angulo P, Batts KP, Jorgensen RA, LaRusso NA, Lindor KD. Oral budesonide in the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000; 95: 23332337.
    Direct Link:
  • 25
    Jawett SL. Azathioprine treatment in primary sclerosing cholangitis. Lancet 1971; i: 810811.
  • 26
    Wagner A. Azathioprine treatment in primary sclerosing cholangitis. Lancet 1971; ii: 663664.
  • 27
    Knox TA, Kaplan MM. Treatment of primary sclerosing cholangitis with oral methotrexate. Am J Gastroenterol 1991; 86: 546542.
  • 28
    Knox TA, Kaplan MM. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology 1994; 106: 494499.
  • 29
    Lindor KD, Jorgensen RA, Andersson ML, Gores GJ, Hofmannn AF, LaRusso NF. Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study. Am J Gastroenterol 1996; 91: 511515.
  • 30
    LaRusso NF, Wiesner RH, Ludwig J, MacCarty RL, Beaver SJ, Zinsmeister AR. Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology 1988; 95: 10361042.
  • 31
    Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid “mechanism of action and clinical use in hepatobiliary disorders”. J Hepatol 2001; 35: 134146.
  • 32
    Yoshikawa M, Tsujii T, Matsumura K, Yamao J, Matsumura Y, Kubo R, et al. Immunomodulatory effects of ursodeoxycholic acid on immune responses. HEPATOLOGY 1992; 16: 358364.
  • 33
    Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effects of ursodeoxycholic acid. HEPATOLOGY 1990; 11: 1215.
  • 34
    Terasaki S, Nakanuma Y, Ogino H, Unoura M, Kabayashi K. Hepatocellular and biliary expression of HLA antigens in primary biliary cirrhosis. Before and after ursodeoxycholic acid therapy. Am J Gastroenterol 1991; 86: 11941199.
  • 35
    Calmus Y, Arvieux C, Gane P, Boucher E, Nordlinger B, Rouger P, et al. Cholestasis induces major histocompatibility complex class I expression in hepatocytes. Gastroenterology 1992; 102: 13711377.
  • 36
    Stiehl A, Walker S, Stiehl L, Rudolph G, Hofmann WJ, Thielmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol 1994; 20: 5764.
  • 37
    Harnois DM, Angulo P, Jorgensen RA, LaRusso NF, Lindor KD. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001; 96: 15581562.
    Direct Link:
  • 38
    Angulo P, Jorgensen RA, Lindor KD. Incomplete response to ursodeoxycholic acid in biliary cirrhosis: is a double dosage worthwhile? Am J Gastroenterol 2001; 96: 31523157.
    Direct Link:
  • 39
    Beuers U, Spengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. HEPATOLOGY 1992; 16: 707714.
  • 40
    Brandsaeter B, Isoniemi H, Broomé U, Olausson M, Backman L, Hansen B, et al. Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol 2004; 40: 815822.
  • 41
    Stiehl A, Rudolph G, Kloters-Plachky P, Sauer P, Walker S. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol 2002; 36: 151156.
  • 42
    Olsson R, Hägerstrand I, Broomé U, Danielsson Å, Järnerot G, Lööf L, et al. Sampling variability of percutaneous liver biopsy in primary sclerosing cholangitis. J Clin Pathol 1995; 48: 993935.
  • 43
    Burak KW, Angulo P, Lindor KD. Is there a role for liver biopsy in primary sclerosing cholangitis? Am J Gastroenterol 2003; 98: 11551158.
    Direct Link:
  • 44
    Ponsioen CY, Vrouenraets SM, Prawirodirdjo W, Rajaram R, Rauws EA, Mulder CJ, et al. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut 2002; 51: 562566.